It has been reported that everolimus, an mTOR inhibitor, presents significant clinical efficacy in improving subependymal giant cell astrocytoma (SEGA), angiomyolipoma (AML), lymphangioleiomyomatosis (LAM), and facial angiofibroma caused by TSC 7-9. Here, MTOR is linked to lymphangioleiomyomatosis.